144 related articles for article (PubMed ID: 38477755)
1. The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression.
Zhang Y; Sun H; Huang F; Chen Y; Ding X; Zhou C; Wu Y; Zhang Q; Ma X; Wang J; Yue R; Shen L; Sun X; Ye Z
J Bone Miner Res; 2024 Mar; ():. PubMed ID: 38477755
[TBL] [Abstract][Full Text] [Related]
2. Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca
Zou B; Zheng J; Deng W; Tan Y; Jie L; Qu Y; Yang Q; Ke M; Ding Z; Chen Y; Yu Q; Li X
Phytomedicine; 2021 Jan; 80():153377. PubMed ID: 33126167
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of protein S-palmitoylation suppresses osteoclastogenesis and ameliorates ovariectomy-induced bone loss.
Ma L; Zhang L; Liao Z; Xiu C; Luo X; Luo N; Zhang L; He G; Chen J
J Orthop Translat; 2023 Sep; 42():1-14. PubMed ID: 37521493
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin prevents ovariectomy-induced osteoporosis by regulating osteoclastic resorption and osteoblastic formation.
Cheon YH; Lee CH; Kim S; Park GD; Kwak SC; Cho HJ; Kim JY; Lee MS
Biomed Pharmacother; 2021 Jul; 139():111697. PubMed ID: 34243614
[TBL] [Abstract][Full Text] [Related]
5. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
6. Sclareol inhibits RANKL-induced osteoclastogenesis and promotes osteoblastogenesis through promoting CCN1 expression via repressing the MAPK pathway.
Li X; Wang Y; Li L; Zhou S; Zhao F
Cell Biol Toxicol; 2021 Dec; 37(6):849-871. PubMed ID: 33423118
[TBL] [Abstract][Full Text] [Related]
7. Sialylation of TLR2 initiates osteoclast fusion.
Dou C; Zhen G; Dan Y; Wan M; Limjunyawong N; Cao X
Bone Res; 2022 Mar; 10(1):24. PubMed ID: 35232979
[TBL] [Abstract][Full Text] [Related]
8. Anti-Siglec-15 antibody suppresses bone resorption by inhibiting osteoclast multinucleation without attenuating bone formation.
Tsukazaki H; Kikuta J; Ao T; Morimoto A; Fukuda C; Tsuda E; Minoshima M; Kikuchi K; Kaito T; Ishii M
Bone; 2021 Nov; 152():116095. PubMed ID: 34216837
[TBL] [Abstract][Full Text] [Related]
9. SENP3 Suppresses Osteoclastogenesis by De-conjugating SUMO2/3 from IRF8 in Bone Marrow-Derived Monocytes.
Zhang Y; Yang K; Yang J; Lao Y; Deng L; Deng G; Yi J; Sun X; Wang Q
Cell Rep; 2020 Feb; 30(6):1951-1963.e4. PubMed ID: 32049023
[TBL] [Abstract][Full Text] [Related]
10. Surfactin suppresses osteoclastogenesis via the NF-κB signaling pathway, promotes osteogenic differentiation in vitro, and inhibits oestrogen deficiency-induced bone loss in vivo.
Kuang Z; Yang X; Cao Z; Li Y; Hu J; Hong X; Li B; Wu C; Qi Q; Liu X; Dai M
Int Immunopharmacol; 2023 Apr; 117():109884. PubMed ID: 36805201
[TBL] [Abstract][Full Text] [Related]
11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
12. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
13. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
Liu FL; Chen CL; Lai CC; Lee CC; Chang DM
Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
[TBL] [Abstract][Full Text] [Related]
14. Water extract of Spatholobus suberectus inhibits osteoclast differentiation and bone resorption.
Ha H; Shim KS; An H; Kim T; Ma JY
BMC Complement Altern Med; 2013 May; 13():112. PubMed ID: 23692684
[TBL] [Abstract][Full Text] [Related]
15. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.
Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X
Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889
[TBL] [Abstract][Full Text] [Related]
16. Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo.
Sun P; Yang Q; Wang Y; Peng J; Zhao K; Jia Y; Zhang T; Lu X; Han W; Qian Y
Drug Des Devel Ther; 2020; 14():4189-4203. PubMed ID: 33116407
[TBL] [Abstract][Full Text] [Related]
17. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
18. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
19. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
[TBL] [Abstract][Full Text] [Related]
20. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
